STUDY OF CHANGES IN TUMOR BLOOD FLOW FOR THE ASSESSMENT OF EARLY RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS
Background. Over the past 20 years, there has been a change in approaches to the treatment of breast cancer, in particular, a significant increase in the role of drug therapy. Breast cancer response to neoadjuvant chemotherapy is currently considered as a surrogate biomarker, which allows evaluation...
Main Authors: | M. V. Pavlov, P. I. Rykhtik, O. E. Ilyinskaya, P. V. Subochev, Yu. M. Kreinina, A. V. Maslennikova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Tomsk National Research Medical Center of the Russian Academy of Sciences
2020-12-01
|
Series: | Sibirskij Onkologičeskij Žurnal |
Subjects: | |
Online Access: | https://www.siboncoj.ru/jour/article/view/1639 |
Similar Items
-
Breast cancer biomarker (ER, PR, HER2) changes in the phenotype after neoadjuvant treatment
by: V. O. Bashlyk, et al.
Published: (2018-07-01) -
Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial
by: Renaud Sabatier, et al.
Published: (2021-01-01) -
Mirna21 Expression in the Breast Cancer Tumor Tissue is Independent of Neoadjuvant Chemotherapy
by: Sales ACV, et al.
Published: (2020-10-01) -
Neoadjuvant chemotherapy in neonatal Wilms′ tumor
by: Ramesh K Reddy, et al.
Published: (2015-01-01) -
The main markers of the long-term efficiency of neoadjuvant chemotherapy in breast cancer (review of literature)
by: V F Semiglazov, et al.
Published: (2013-12-01)